Functional analysis of GNG2 in human malignant melanoma cells

Journal of Dermatological Science

Volumn 68, Issue 3, 2012, Pages 172-178

  Yajima, Ichiro ^a   Kumasaka, Mayuko Y ^a   Tamura, Haruka ^a   Ohgami, Nobutaka ^a   Kato, Masashi ^a  

^a CHUBU UNIVERSITY   (Japan)

Author keywords

G protein; Gamma subunit; Malignant melanoma; Proliferation

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; ENDOTHELIN 1; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR B; GUANINE NUCLEOTIDE BINDING PROTEIN GAMMA SUBUNIT; GUANINE NUCLEOTIDE BINDING PROTEIN GAMMA SUBUNIT 2; PROTEIN KINASE B; PROTEIN KINASE P60; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOTHELIN-1; GENE KNOCKDOWN TECHNIQUES; GTP-BINDING PROTEINS; HUMANS; MELANOMA; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; RECEPTOR, ENDOTHELIN B; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSPLANTATION, HETEROLOGOUS; UP-REGULATION;

EID: 84868569682     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2012.09.009     Document Type: Article

References (31)

1. Hussein M.R. Melanocytic dysplastic naevi occupy the middle ground between benign melanocytic naevi and cutaneous malignant melanomas: emerging clues. J Clin Pathol 2005, 58:453-456.
2. Chin L., Garraway L.A., Fisher D.E. Malignant melanoma: genetics and therapeutics in the genomic era. Genes Dev 2006, 20:2149-2182.
3. Yajima I., Kumasaka M.Y., Thang N.D., Goto Y., Takeda K., Iida M., et al. Molecular network associated with MITF in skin melanoma development and progression. J Skin Cancer 2011, 2011:730170.
4. Yajima I., Kumasaka M.Y., Thang N.D., Goto Y., Takeda K., Yamanoshita O., et al. RAS/RAF/MEK/ERK and PI3K/PTEN/AKT signaling in malignant melanoma progression and therapy. Dermatol Res Pract 2011, 2012:354191.
5. Leung T., Chen H., Stauffer A.M., Giger K.E., Sinha S., Horstick E.J., et al. Zebrafish G protein gamma2 is required for VEGF signaling during angiogenesis. Blood 2006, 108:160-166.
6. Schwindinger W.F., Robishaw J.D. Heterotrimeric G-protein betagamma-dimers in growth and differentiation. Oncogene 2001, 20:1653-1660.
7. Dorsam R.T., Gutkind J.S. G-protein-coupled receptors and cancer. Nat Rev Cancer 2007, 7:79-94.
8. Luttrell L.M., Hawes B.E., van Biesen T., Luttrell D.K., Lansing T.J., Lefkowitz R.J. Role of c-Src tyrosine kinase in G protein-coupled receptor- and Gbetagamma subunit-mediated activation of mitogen-activated protein kinases. J Biol Chem 1996, 271:19443-19450.
9. Kato M., Liu W., Akhand A.A., Dai Y., Ohbayashi M., Tuzuki T., et al. Linkage between melanocytic tumor development and early burst of Ret protein expression for tolerance induction in metallothionein-I/ret transgenic mouse lines. Oncogene 1999, 18:837-842.
10. Kato M., Takeda K., Kawamoto Y., Tsuzuki T., Hossain K., Tamakoshi A., et al. c-Kit-targeting immunotherapy for hereditary melanoma in a mouse model. Cancer Res 2004, 64:801-806.
11. Kato M., Hattori T., Ito H., Kageyama M., Yamashita T., Nitta Y., et al. Serum-soluble Fas levels as a marker to distinguish allergic and nonallergic rhinitis. J Allergy Clin Immunol 1999, 103:1213-1214.
12. Yajima I., Mayuko Y.K., Naito Y., Yoshikawa T., Takahashi H., Funasaka Y., et al. Reduced GNG2 expression levels in mouse malignant melanomas and human melanoma cell lines. Am J Cancer Res 2012, 2:322-329.
13. Kato M., Wickner W. Vam10p defines a Sec18p-independent step of priming that allows yeast vacuole tethering. Proc Natl Acad Sci USA 2003, 100:6398-6403.
14. Kumasaka M.Y., Yajima I., Hossain K., Iida M., Tsuzuki T., Ohno T., et al. A novel mouse model for de novo melanoma. Cancer Res 2010, 70:24-29.
15. Ohgami N., Ida-Eto M., Shimotake T., Sakashita N., Sone M., Nakashima T., et al. c-Ret-mediated hearing loss in mice with Hirschsprung disease. Proc Natl Acad Sci USA 2010, 107:13051-13056.
16. Kato M., Iida M., Goto Y., Kondo T., Yajima I. Sunlight exposure-mediated DNA damage in young adults. Cancer Epidemiol Biomarkers Prev 2011, 20:1622-1628.
17. Bittner M., Meltzer P., Chen Y., Jiang Y., Seftor E., Hendrix M., et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000, 406:536-540.
18. Demunter A., De Wolf-Peeters C., Degreef H., Stas M., van den Oord J.J. Expression of the endothelin-B receptor in pigment cell lesions of the skin. Evidence for its role as tumor progression marker in malignant melanoma. Virchows Arch 2001, 438:485-491.
19. Bagnato A., Rosano L., Spinella F., Di Castro V., Tecce R., Natali P.G., et al. receptor blockade inhibits dynamics of cell interactions and communications in melanoma cell progression. Cancer Res 2004, 64:1436-1443.
20. Hiscox S., Morgan L., Green T., Nicholson R.I. Src as a therapeutic target in anti-hormone/anti-growth factor-resistant breast cancer. Endocr Relat Cancer 2006, 13(Suppl. 1):S53-S59.
21. Homsi J., Cubitt C., Daud A. The Src signaling pathway: a potential target in melanoma and other malignancies. Expert Opin Ther Targets 2007, 11:91-100.
22. Irby R.B., Mao W., Coppola D., Kang J., Loubeau J.M., Trudeau W., et al. Activating SRC mutation in a subset of advanced human colon cancers. Nat Genet 1999, 21:187-190.
23. Nam S., Kim D., Cheng J.Q., Zhang S., Lee J.H., Buettner R., et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2005, 65:9185-9189.
24. Mayo L.D., Dixon J.E., Durden D.L., Tonks N.K., Donner D.B. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem 2002, 277:5484-5489.
25. Zhou B.P., Liao Y., Xia W., Zou Y., Spohn B., Hung M.C. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat Cell Biol 2001, 3:973-982.
26. Bennett D.C. How to make a melanoma: what do we know of the primary clonal events?. Pigment Cell Melanoma Res 2008, 21:27-38.
27. Straume O., Sviland L., Akslen L.A. Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res 2000, 6:1845-1853.
28. Lopez-Ilasaca M., Crespo P., Pellici P.G., Gutkind J.S., Wetzker R. Linkage of G protein-coupled receptors to the MAPK signaling pathway through PI 3-kinase gamma. Science 1997, 275:394-397.
29. Shibata K., Mori M., Tanaka S., Kitano S., Akiyoshi T. Identification and cloning of human G-protein gamma 7, down-regulated in pancreatic cancer. Biochem Biophys Res Commun 1998, 246:205-209.
30. Shibata K., Tanaka S., Shiraishi T., Kitano S., Mori M. G-protein gamma 7 is down-regulated in cancers and associated with p 27kip1-induced growth arrest. Cancer Res 1999, 59:1096-1101.
31. Dupre D.J., Robitaille M., Richer M., Ethier N., Mamarbachi A.M., Hebert T.E. Dopamine receptor-interacting protein 78 acts as a molecular chaperone for Ggamma subunits before assembly with Gbeta. J Biol Chem 2007, 282:13703-13715.